falsefalse

Evolving Treatment Approaches After Checkpoint Inhibition in Advanced Melanoma - Episode 3

The Promise of Oncolytic Viruses in Advanced Melanoma

,

Michael A. Postow, MD, and Chenyang Zhan, MD, PhD, dive into research behind oncolytic viruses in advanced melanoma.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
  • Chapters
  • descriptions off, selected
  • captions off, selected
    EP. 1: Treatment Challenges After Immunotherapy in Advanced Melanoma
    EP. 2: The Role of Interventional Radiologists in Advanced Melanoma Management
    Now Viewing
    EP. 3: The Promise of Oncolytic Viruses in Advanced Melanoma
    EP. 4: Data for RP1 Plus Nivolumab in Metastatic Melanoma After Prior PD-1 Inhibition
    EP. 5: Where RP1 Plus Nivolumab Could Fit in the Treatment Paradigm for Advanced Melanoma Post–PD-1 Inhibition
    EP. 6: Key Areas of Future Research in Advanced Melanoma

    Related Content:

    Evolving Treatment Approaches After Checkpoint Inhibition in Advanced MelanomaMemorial Sloan Kettering Cancer Center OncLive News Network®Melanoma & Skin Cancer
    Accelerated FDA Approval Establishes Role of Avutometinib/Defactinib in KRAS-Mutant Recurrent Low-Grade Serous Ovarian Cancer
    Dostarlimab Plus Cobolimab Improves MPR Rate vs Dostarlimab in High-Risk Resectable Melanoma
    Adjuvant Encorafenib/Binimetinib Is Well Tolerated and May Reduce Recurrence Risk in BRAF V600–Mutant Melanoma
    x